PHAT - Phathom says mid-stage study for vonoprazan in gastroesophageal reflux met main goal

Announcing topline data from its PHALCON-NERD trial for vonoprazan, Phathom Pharmaceuticals (NASDAQ:PHAT) said that the experimental on-demand therapy for episodic heartburn met the main goal in subjects with non-erosive gastroesophageal reflux disease (NERD). In reaction, Phathom (PHAT) shares have added ~9% in the post-market. In the Phase 2 study, vonoprazan achieved the primary endpoint with statistical significance across all three dose levels (10 mg, 20 mg, and 40 mg) compared to the placebo. In the open-label daily dosing run-in phase of the trial where participants received vonoprazan 20 mg once daily (QD) for four weeks, the mean percentage of 24-hour heartburn-free days was 65.4% (median 76.0%). No more than three percent of subjects experienced an adverse event, and four serious adverse events (SAEs) were reported in the daily dosing phase. No SAEs were found in the on-demand phase. The company has begun a Phase 3 study to study vonoprazan at 10 mg

For further details see:

Phathom says mid-stage study for vonoprazan in gastroesophageal reflux met main goal